Literature DB >> 32306110

Endoscopic treatment of pouch inlet and afferent limb strictures: stricturotomy vs. balloon dilation.

Nan Lan1, Jin-Jie Wu2, Xian-Rui Wu1,2, Tracy L, Bo Shen3.   

Abstract

BACKGROUND: Strictures are common complications after ileal pouch surgery. The aim of this study is to evaluate the efficacy and safety of endoscopic stricturotomy vs. endoscopic balloon dilation (EBD) in the treatment of pouch inlet strictures.
METHODS: All consecutive ulcerative colitis patients with the diagnosis of pouch inlet or afferent limb strictures treated in our Interventional Inflammatory Bowel Disease Unit (i-IBD) from 2008 to 2017 were extracted. The primary outcomes were surgery-free survival and post-procedural complications.
RESULTS: A total of 200 eligible patients were included in this study, with 40 (20.0%) patients treated with endoscopic stricturotomy and 160 (80.0%) patients treated with EBD. Symptom improvement was recorded in 11 (42.3%) patients treated with endoscopic stricturotomy and 16 (13.2%) treated with EBD. Subsequent surgery rate was comparable between the two groups (9 [22.5%] vs. 33 [20.6%], P = 0.80) during a median follow-up of 0.6 years (interquartile range [IQR] 0.4-0.8) vs. 3.6 years (IQR 1.1-6.2) in patients receiving endoscopic stricturotomy and EBD, respectively. The overall surgery-free survival seems to be comparable as well (P = 0.12). None of the patients in the stricturotomy group developed pouch failure, while 9 patients (5.6%) had pouch failure in the balloon dilation group (P = 0.17). Procedural bleeding was seen in three occasions (4.7% per procedure) in patients receiving endoscopic stricturotomy and perforation was seen in three occasions (0.8% per procedure) in patients receiving EBD (P = 0.02). In multivariable analysis, an increased length of the stricture (hazard ratio [HR] 1.4, 95% confidence interval [CI] 1.0-1.8) and concurrent pouchitis (HR 2.5, 95% CI 1.0-5.7) were found to be risk factors for the requirement of surgery.
CONCLUSION: Endoscopic stricturotomy and EBD were both effective in treating patients with pouch inlet or afferent limb strictures, EBD had a higher perforation risk while endoscopic stricturotomy had a higher bleeding risk.

Entities:  

Keywords:  Balloon dilation; Endoscopy; Ileal pouch–anal anastomosis; Inlet; Stricture; Stricturotomy; Ulcerative colitis

Mesh:

Year:  2020        PMID: 32306110     DOI: 10.1007/s00464-020-07562-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  1 in total

1.  Rendezvous computed tomography-assisted endoscopic needle-knife stricturotomy for sealed outlet of diverted large bowel.

Authors:  Custon T Nyabanga; Joseph C Veniero; Bo Shen
Journal:  Endoscopy       Date:  2015-12-29       Impact factor: 10.093

  1 in total
  4 in total

Review 1.  Therapeutic Endoscopy in Postoperative Pouch Complications.

Authors:  Saurabh Chandan; Bo Shen; Gursimran S Kochhar
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

Review 2.  Interventional inflammatory bowel disease: endoscopic therapy of complications of Crohn's disease.

Authors:  Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-09-14

3.  Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update.

Authors:  Andrew M Veitch; Franco Radaelli; Raza Alikhan; Jean-Marc Dumonceau; Diane Eaton; Jo Jerrome; Will Lester; David Nylander; Mo Thoufeeq; Geoffroy Vanbiervliet; James R Wilkinson; Jeanin E van Hooft
Journal:  Endoscopy       Date:  2021-08-06       Impact factor: 10.093

4.  Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update.

Authors:  Andrew M Veitch; Franco Radaelli; Raza Alikhan; Jean Marc Dumonceau; Diane Eaton; Jo Jerrome; Will Lester; David Nylander; Mo Thoufeeq; Geoffroy Vanbiervliet; James R Wilkinson; Jeanin E Van Hooft
Journal:  Gut       Date:  2021-09       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.